Target site occupancy: Emerging generalizations from clinical and preclinical studies

Pharmacology and Therapeutics

Volumn 122, Issue 3, 2009, Pages 281-301

  Grimwood, Sarah ^a   Hartig, Paul R ^b  

^a PFIZER INC   (United States)

^b Cogenta LLC ^*  (United States)

Author keywords

G protein coupled receptor; Positron Emission Tomography; Receptor reserve; Single Photon Emission Computed Tomography; Target biomarker; Target site occupancy

Indexed keywords

AMISULPRIDE; BIOLOGICAL MARKER; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DROPERIDOL; EPIDEPRIDE; FLUPENTIXOL; FLUPHENAZINE; G PROTEIN COUPLED RECEPTOR; HALOPERIDOL; ION CHANNEL; ISOREMOXIPRIDE; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; NEUROTRANSMITTER TRANSPORTER; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PINDOLOL; QUETIAPINE; RACLOPRIDE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; UNINDEXED DRUG; ZUCLOPENTHIXOL;

CHANNEL GATING; DRUG BINDING SITE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESEARCH; HUMAN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS;

EID: 67349097389     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2009.03.002     Document Type: Review

References (303)

1. Abadie P., Rioux P., Scatton B., Zarifian E., Barre L., Patat A., et al. Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography. Eur J Pharmacol 295 (1996) 35-44
2. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97 (2000) 8104-8109
3. Abi-Dargham A., Simpson N., Kegeles L., Parsey R., Hwang D.R., Anjilvel S., et al. PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse 32 (1999) 93-109
4. Abramow-Newerly M., Roy A.A., Nunn C., and Chidiac P. RGS proteins have a signalling complex: interactions between RGS proteins and GPCRs, effectors, and auxiliary proteins. Cell Signal 18 (2006) 579-591
5. Adams J.U., Paronis C.A., and Holtzman S.G. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine. J Pharmacol Exp Ther 255 (1990) 1027-1032
6. Adham N., Ellerbrock B., Hartig P., Weinshank R.L., and Branchek T. Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor expression system. Mol Pharmacol 43 (1993) 427-433
7. Adler C.H., Meller E., and Goldstein M. Receptor reserve at the alpha-2 adrenergic receptor in the rat cerebral cortex. J Pharmacol Exp Ther 240 (1987) 508-515
8. Agid O., Mamo D., Ginovart N., Vitcu I., Wilson A.A., Zipursky R.B., et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response-a double-blind PET study in schizophrenia. Neuropsychopharmacology 32 (2007) 1209-1215 Electronic publication 2006 Nov 1
9. Ananth J., Burgoyne K.S., Gadasalli R., and Aquino S. How do the atypical antipsychotics work?. J Psychiatry Neurosci 26 (2001) 385-394
10. Anderson J.J., Bradbury M.J., Giracello D.R., Chapman D.F., Holtz G., Roppe J., et al. In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine). Eur J Pharmacol 473 (2003) 35-40
11. Andree B., Thorberg S.O., Halldin C., and Farde L. Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology (Berlin) 144 (1999) 303-305
12. Angst J., and Stabl M. Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology (Berlin) 106 (1992) S109-113
13. Atack J.R., Alder L., Cook S.M., Smith A.J., and McKernan R.M. In vivo labelling of alpha5 subunit-containing GABA(A) receptors using the selective radioligand [(3)H]L-655,708. Neuropharmacology 49 (2005) 220-229
14. Atack J.R., Hutson P.H., Collinson N., Marshall G., Bentley G., Moyes C., et al. Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors. Br J Pharmacol 144 (2005) 357-366
15. Atack J.R., Pike A., Marshall G., Stanley J., Lincoln R., Cook S.M., et al. The in vivo properties of pagoclone in rat are most likely mediated by 5′-hydroxy pagoclone. Neuropharmacology 50 (2006) 677-689
16. Atack J.R., Wafford K.A., Tye S.J., Cook S.M., Sohal B., Pike A., et al. TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-flu or ophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. J Pharmacol Exp Ther 316 (2006) 410-422
17. Atack J.R., Scott-Stevens P., Beech J.S., Fryer T.D., Hughes J.L., Cleij M.C., et al. Comparison of lorazepam [7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin- 2-one] occupancy of rat brain {gamma}-aminobutyric acidA receptors Measured using in vivo [3H]flumazenil (8-fluoro 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carbox yl ic acid ethyl ester) binding and [11C]flumazenil micro-positron emission tomography. J Pharmacol Exp Ther 320 (2007) 1030-1037
18. Atack J.R., Smith A.J., Emms F., and McKernan R.M. Regional differences in the inhibition of mouse in vivo [3H]Ro 15-1788 binding reflect selectivity for alpha 1 versus alpha 2 and alpha 3 subunit-containing GABAA receptors. Neuropsychopharmacology 20 (1999) 255-262
19. Auclair A.L., Kleven M.S., Besnard J., Depoortere R., and Newman-Tancredi A. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Neuropsychopharmacology 31 (2006) 1900-1909
20. Bagdy G., and To C.T. Comparison of relative potencies of i.v. and i.c.v. administered 8-OH-DPAT gives evidence of different sites of action for hypothermia, lower lip retraction and tail flicks. Eur J Pharmacol 323 (1997) 53-58
21. Bajo M., Crawford E.F., Roberto M., Madamba S.G., and Siggins G.R. Chronic morphine treatment alters expression of N-methyl-d-aspartate receptor subunits in the extended amygdala. J Neurosci Res 83 (2006) 532-537
22. Bansal G., Druey K.M., and Xie Z. R4 RGS proteins: regulation of G-protein signaling and beyond. Pharmacol Ther 116 (2007) 473-495
23. Bantick R.A., Rabiner E.A., Hirani E., de Vries M.H., Hume S.P., and Grasby P.M. Occupancy of agonist drugs at the 5-HT1A receptor. Neuropsychopharmacology 29 (2004) 847-859
24. Barros M., Mello E.L., Maior R.S., Muller C.P., de Souza Silva M.A., Carey R.J., et al. Anxiolytic-like effects of the selective 5-HT1A receptor antagonist WAY 100635 in non-human primates. Eur J Pharmacol 482 (2003) 197-203
25. Barth V.N., Chernet E., Martin L.J., Need A.B., Rash K.S., Morin M., et al. Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer. Life Sci 78 (2006) 3007-3012
26. Bigliani V., Mulligan R.S., Acton P.D., Ohlsen R.I., Pike V.W., Ell P.J., et al. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study. Psychopharmacology (Berlin) 150 (2000) 132-140
27. Bigliani V., Mulligan R.S., Acton P.D., Visvikis D., Ell P.J., Stephenson C., et al. In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123I]epidepride single photon emission tomography (SPET) study. Br J Psychiatry 175 (1999) 231-238
28. Blier P., Seletti B., Gilbert F., Young S.N., and Benkelfat C. Serotonin 1A receptor activation and hypothermia in humans: lack of evidence for a presynaptic mediation. Neuropsychopharmacology 27 (2002) 301-308
29. Blier P., and Ward N.M. Is there a role for 5-HT1A agonists in the treatment of depression?. Biol Psychiatry 53 (2003) 193-203
30. Borgland S.L. Acute opioid receptor desensitization and tolerance: is there a link?. Clin Exp Pharmacol Physiol 28 (2001) 147-154
31. Bressan R.A., Erlandsson K., Jones H.M., Mulligan R.S., Ell P.J., and Pilowsky L.S. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J Clin Psychopharmacol 23 (2003) 5-14
32. Bressan R.A., Erlandsson K., Jones H.M., Mulligan R., Flanagan R.J., Ell P.J., et al. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 160 (2003) 1413-1420
33. Bressan R.A., Erlandsson K., Spencer E.P., Ell P.J., and Pilowsky L.S. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology (Berlin) 175 (2004) 367-373
34. Brooks D.J. Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. NeuroRx 2 (2005) 226-236
35. Brouillet E., Chavoix C., Bottlaender M., Khalili-Varasteh M., Hantraye P., Fournier D., et al. In vivo bidirectional modulatory effect of benzodiazepine receptor ligands on GABAergic transmission evaluated by positron emission tomography in non-human primates. Brain Res 557 (1991) 167-176
36. Bruins Slot L.A., De Vries L., Newman-Tancredi A., and Cussac D. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol 534 (2006) 63-70
37. Bylund D.B., and Toews M.L. Radioligand binding methods: practical guide and tips. Am J Physiol 265 (1993) L421-429
38. Chatziioannou A.F. Molecular imaging of small animals with dedicated PET tomographs. Eur J Nucl Med Mol Imaging 29 (2002) 98-114
39. Chernet E., Martin L.J., Li D., Need A.B., Barth V.N., Rash K.S., et al. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples. Life Sci 78 (2005) 340-346
40. Cherry S.R., and Gambhir S.S. Use of positron emission tomography in animal research. ILAR J 42 (2001) 219-232
41. Chou Y.H., Halldin C., and Farde L. Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study. Psychopharmacology (Berlin) 185 (2006) 29-35
42. Christopoulos A., and El-Fakahany E.E. Qualitative and quantitative assessment of relative agonist efficacy. Biochem Pharmacol 58 (1999) 735-748
43. Claustre Y., Peretti D.D., Brun P., Gueudet C., Allouard N., Alonso R., et al. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: neurochemical and electrophysiological profile. Neuropsychopharmacology 28 (2003) 2064-2076
44. + channels in pancreatic beta-cells. Spare-channel hypothesis. Diabetes 37 (1988) 495-498
45. Cosi C., Carilla-Durand E., Assie M.B., Ormiere A.M., Maraval M., Leduc N., et al. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol 535 (2006) 135-144
46. Costa G., Isla M., Garcia-Pascual A., Jimenez E., Recio P., Labadia A., et al. Characterization of postsynaptic alpha-adrenoceptors in the arteries supplying the oviduct. Br J Pharmacol 105 (1992) 381-387
47. Cox R.F., and Waszczak B.L. Irreversible receptor inactivation reveals differences in dopamine receptor reserve between A9 and A10 dopamine systems: an electrophysiological analysis. Brain Res 534 (1990) 273-282
48. Cox R.F., and Waszczak B.L. Inhibition of substantia nigra dopamine cell firing by R(-)-N-n-propylnorapomorphine: electrophysiological and autoradiographic studies after regional inactivation of dopamine receptors by microinjection of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Brain Res 613 (1993) 32-42
49. Cryan J.F., Kelliher P., Kelly J.P., and Leonard B.E. Comparative effects of serotonergic agonists with varying efficacy at the 5-HT(1A) receptor on core body temperature: modification by the selective 5-HT(1A) receptor antagonist WAY 100635. J Psychopharmacol 13 (1999) 278-283
50. Cumming P., Wong D.F., Gillings N., Hilton J., Scheffel U., and Gjedde A. Specific binding of [(11)C]raclopride and N-[(3)H]propyl-norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein. J Cereb Blood Flow Metab 22 (2002) 596-604
51. Cumming P., Wong D.F., Dannals R.F., Gillings N., Hilton J., Scheffel U., et al. The competition between endogenous dopamine and radioligands for specific binding to dopamine receptors. Ann N Y Acad Sci 965 (2002) 440-450
52. Danhof M., de Lange E.C., Della Pasqua O.E., Ploeger B.A., and Voskuyl R.A. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 29 (2008) 186-191
53. DaSilva J.N., Lourenco C.M., Meyer J.H., Hussey D., Potter W.Z., and Houle S. Imaging cAMP-specific phosphodiesterase-4 in human brain with R-[11C]rolipram and positron emission tomography. Eur J Nucl Med Mol Imaging 29 (2002) 1680-1683 Electronic publication 2002 Oct 2
54. Dawson G.R., Maubach K.A., Collinson N., Cobain M., Everitt B.J., MacLeod A.M., et al. An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition. J Pharmacol Exp Ther 316 (2006) 1335-1345
55. Delcourt N., Bockaert J., and Marin P. GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation. Trends Pharmacol Sci 28 (2007) 602-607
56. De Lean A., Stadel J.M., and Lefkowitz R.J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem 255 (1980) 7108-7117
57. de Ligt R.A., Kourounakis A.P., and AP I.J. Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol 130 (2000) 1-12
58. Depoortere R., Boulay D., Perrault G., Bergis O., Decobert M., Francon D., et al. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology 28 (2003) 1889-1902
59. De Vries M.H., Udo de Haes J., Long S.K., Grahnén A., Nyman L., Bergström M., et al. DU 127090: a highly potent, atypical dopamine receptor ligand - pilot study of dopamine D2 receptor occupancy after multiple oral administration of DU 127090 to healthy male volunteers, using 11C-raclopride by means of positron emission tomography. Eur Neuropsychopharmacol 10 (2000) S294
60. De Vry J. 5-HT1A receptor agonists: recent developments and controversial issues. Psychopharmacology (Berlin) 121 (1995) 1-26
61. Dias R., Sheppard W.F., Fradley R.L., Garrett E.M., Stanley J.L., Tye S.J., et al. Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci 25 (2005) 10682-10688
62. Ding Y.S., Lin K.S., and Logan J. PET imaging of norepinephrine transporters. Curr Pharm Des. 12 (2006) 3831-3845
63. Dobbs F.R., Banks W., Fleishaker J.C., Valentine A.D., Kinsey B.M., Franceschini M.P., et al. Studies with [11C]alprazolam: an agonist for the benzodiazepine receptor. Nucl Med Biol 22 (1995) 459-466
64. Duffy R.A., Varty G.B., Morgan C.A., and Lachowicz J.E. Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists. J Pharmacol Exp Ther 301 (2002) 536-542
65. Dumont F., Waterhouse R.N., Montoya J.A., Mattner F., Katsifis A., Kegeles L.S., et al. Synthesis and in vivo evaluation of [11C]zolpidem, an imidazopyridine with agonist properties at central benzodiazepine receptors. Nucl Med Biol 30 (2003) 435-439
66. Dutriez I., Lagny-Pourmir I., Epelbaum J., and Beauvillain J.C. Autoradiographic quantitation and anatomical mapping of GTP sensitive-galanin receptors in the guinea pig central nervous system. J Chem Neuroanat 12 (1996) 85-104
67. Edwardson J.M., and Szekeres P.G. Endocytosis and recycling of muscarinic receptors. Life Sci 64 (1999) 487-494
68. Ehlert F.J. Analysis of allosterism in functional assays. J Pharmacol Exp Ther 315 (2005) 740-754
69. Eisinger D.A., and Schulz R. Mechanism and consequences of delta-opioid receptor internalization. Crit Rev Neurobiol 17 (2005) 1-26
70. Emerit M.B., Miquel M.C., Gozlan H., and Hamon M. The GTP-insensitive component of high-affinity [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding in the rat hippocampus corresponds to an oxidized state of the 5-hydroxytryptamine1A receptor. J Neurochem 56 (1991) 1705-1716
71. Enz A., Goldstein M., and Meller E. Dopamine agonist-induced elevation of striatal acetylcholine: relationship between receptor occupancy and response in normal and denervated rat striatum. Mol Pharmacol 37 (1990) 560-565
72. Facklam M., Schoch P., Bonetti E.P., Jenck F., Martin J.R., Moreau J.L., et al. Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies. J Pharmacol Exp Ther 261 (1992) 1113-1121
73. Farde L., Nordstrom A.L., Nyberg S., Halldin C., and Sedvall G. D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 55 Suppl B (1994) 67-69
74. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., and Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49 (1992) 538-544
75. Farde L., Nyberg S., Oxenstierna G., Nakashima Y., Halldin C., and Ericsson B. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 15 (1995) 19S-23S
76. Ferguson S.S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53 (2001) 1-24
77. Ferguson S.S., Zhang J., Barak L.S., and Caron M.G. Molecular mechanisms of G protein-coupled receptor desensitization and resensitization. Life Sci 62 (1998) 1561-1565
78. Findlay I., and Faivre J.F. ATP-sensitive K channels in heart muscle. Spare channels. FEBS Lett 279 (1991) 95-97
79. Fischman A.J., Bonab A.A., Babich J.W., Alpert N.M., Rauch S.L., Elmaleh D.R., et al. Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J Pharmacol Exp Ther 279 (1996) 939-947
80. Fitzgerald L.W., Conklin D.S., Krause C.M., Marshall A.P., Patterson J.P., Tran D.P., et al. High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. J Neurochem 72 (1999) 2127-2134
81. Fletcher A., Forster E.A., Bill D.J., Brown G., Cliffe I.A., Hartley J.E., et al. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res 73 (1996) 337-353
82. Fowler J.S., Logan J., Volkow N.D., and Wang G.J. Translational neuroimaging: positron emission tomography studies of monoamine oxidase. Mol Imaging Biol 7 (2005) 377-387
83. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., Shea C., et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A 93 (1996) 14065-14069
84. Fowler J.S., Wang G.J., Volkow N.D., Franceschi D., Logan J., Pappas N., et al. Maintenance of brain monoamine oxidase B inhibition in smokers after overnight cigarette abstinence. Am J Psychiatry 157 (2000) 1864-1866
85. Fowler J.S., Wolf A.P., MacGregor R.R., Dewey S.L., Logan J., Schlyer D.J., et al. Mechanistic positron emission tomography studies: demonstration of a deuterium isotope effect in the monoamine oxidase-catalyzed binding of [11C]l-deprenyl in living baboon brain. J Neurochem 51 (1988) 1524-1534
86. Frankle W.G., Gil R., Hackett E., Mawlawi O., Zea-Ponce Y., Zhu Z., et al. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology (Berlin) 175 (2004) 473-480
87. Freedman S.B., Harley E.A., and Patel S. Direct measurement of muscarinic agents in the central nervous system of mice using ex vivo binding. Eur J Pharmacol 174 (1989) 253-260
88. Freedman N.M., Mishani E., Krausz Y., Weininger J., Lester H., Blaugrund E., et al. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET. J Nucl Med 46 (2005) 1618-1624
89. Fujita M., Woods S.W., Verhoeff N.P., Abi-Dargham A., Baldwin R.M., Zoghbi S.S., et al. Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. Eur J Pharmacol 368 (1999) 161-172
90. Furchgott R.F., and Bursztyn P. Comparison of dissociation constants and relative efficacies of selected agonists acting on parasympathetic receptors. Ann N Y Acad Sci 144 (1967) 882-899
91. Galitzky J., Mauriege P., Berlan M., and Lafontan M. Human fat cell alpha-2 adrenoceptors. I. Functional exploration and pharmacological definition with selected alpha-2 agonists and antagonists. J Pharmacol Exp Ther 249 (1989) 583-591
92. Gatley S.J., Volkow N.D., Fowler J.S., Ding Y.-S., Logan J., Wang G.-J., et al. Positron emission tomography and its use to image the occupancy of drug binding sites. Drug Dev Res 59 (2003) 194-207
93. Gerwins P., Nordstedt C., and Fredholm B.B. Characterization of adenosine A1 receptors in intact DDT1 MF-2 smooth muscle cells. Mol Pharmacol 38 (1990) 660-666
94. Ginovart N., Galineau L., Willeit M., Mizrahi R., Bloomfield P.M., Seeman P., et al. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 97 (2006) 1089-1103
95. Ginovart N., Meyer J.H., Boovariwala A., Hussey D., Rabiner E.A., Houle S., et al. Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain. J Cereb Blood Flow Metab 26 (2006) 330-344
96. Ginovart N., Wilson A.A., Meyer J.H., Hussey D., and Houle S. [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. Synapse 47 (2003) 123-133
97. Gobeil F., Fortier A., Zhu T., Bossolasco M., Leduc M., Grandbois M., et al. G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. Can J Physiol Pharmacol 84 (2006) 287-297
98. Goldstein M.E., Cao Y., Fiedler T., Toyn J., Iben L., Barten D.M., et al. Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice. J Pharmacol Exp Ther 323 (2007) 102-108
99. Gray J.A., and Roth B.L. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 56 (2001) 441-451
100. Greenblatt D.J., and Wright C.E. Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin Pharmacokinet 24 (1993) 453-471
101. Greenwald M.K., Johanson C.E., Moody D.E., Woods J.H., Kilbourn M.R., Koeppe R.A., et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28 (2003) 2000-2009
102. Grimwood S., Richards P., Murray F., Harrison N., Wingrove P.B., and Hutson P.H. Characterisation of N-methyl-d-aspartate receptor-specific [(3)H]Ifenprodil binding to recombinant human NR1a/NR2B receptors compared with native receptors in rodent brain membranes. J Neurochem 75 (2000) 2455-2463
103. Gründer G., Carlsson A., and Wong D.F. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60 (2003) 974-977
104. Guimaraes S., and Paiva M.Q. Postsynaptic alpha-adrenoceptor reserve and the shift of the concentration-response curves to the right, as caused by the irreversible alpha-adrenoceptor antagonist phenoxybenzamine. Br J Pharmacol 92 (1987) 505-512
105. Gurevich V.V., and Gurevich E.V. How and why do GPCRs dimerize?. Trends Pharmacol Sci 29 (2008) 234-240
106. Gutman D.A., Owens M.J., Skelton K.H., Thrivikraman K.V., and Nemeroff C.B. The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. J Pharmacol Exp Ther 304 (2003) 874-880
107. Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry 63 Suppl 11 (2002) 18-24
108. Hausdorff W.P., Caron M.G., and Lefkowitz R.J. Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J 4 (1990) 2881-2889
109. Hayes M.J., Qing F., Rhodes C.G., Rahman S.U., Ind P.W., Sriskandan S., et al. In vivo quantification of human pulmonary beta-adrenoceptors: effect of beta-agonist therapy. Am J Respir Crit Care Med 154 (1996) 1277-1283
110. Hegde S.S. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 147 Suppl 2 (2006) S80-87
111. Heinrichs S.C., De Souza E.B., Schulteis G., Lapsansky J.L., and Grigoriadis D.E. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 27 (2002) 194-202
112. Heiss W.D., and Herholz K. Brain receptor imaging. J Nucl Med 47 (2006) 302-312
113. Hirst W.D., Andree T.H., Aschmies S., Childers W.E., Comery T.A., Dawson L.A., et al. Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohex ane carboxamide (WAY-101405). J Pharmacol Exp Ther 325 (2008) 134-145
114. Hoffman D.C., and Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berlin) 120 (1995) 128-133
115. Hogg R.C., Buisson B., and Bertrand D. Allosteric modulation of ligand-gated ion channels. Biochem Pharmacol 70 (2005) 1267-1276
116. Holtzman S.G. Discriminative stimulus effects of buprenorphine in the rat. Psychopharmacology (Berlin) 130 (1997) 292-299
117. Horacek J., Bubenikova-Valesova V., Kopecek M., Palenicek T., Dockery C., Mohr P., et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20 (2006) 389-409
118. Horowski R., and Dorrow R. Anxiogenic, not psychotogenic, properties of the partial inverse benzodiazepine receptor agonist FG 7142 in man. Psychopharmacology (Berl) 162 (2002) 223-224
119. Hosoi R., Kobayashi K., Watanabe Y., and Inoue O. Evaluation of in vivo binding properties of 3H-NMPB and 3H-QNB in mouse brain. J Neural Transm 106 (1999) 583-592
120. Howell L.L., and Wilcox K.M. Functional imaging and neurochemical correlates of stimulant self-administration in primates. Psychopharmacology (Berlin) 163 (2002) 352-361
121. Hoyer D., and Boddeke H.W. Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol Sci 14 (1993) 270-275
122. Huang Y.H., and Bergles D.E. Glutamate transporters bring competition to the synapse. Curr Opin Neurobiol 14 (2004) 346-352
123. Huganir R.L., and Greengard P. Regulation of neurotransmitter receptor desensitization by protein phosphorylation. Neuron 5 (1990) 555-567
124. Hughes Z.A., Starr K.R., Langmead C.J., Hill M., Bartoszyk G.D., Hagan J.J., et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 510 (2005) 49-57
125. Hume S.P., Lammertsma A.A., Opacka-Juffry J., Ahier R.G., Myers R., Cremer J.E., et al. Quantification of in vivo binding of [3H]RX 821002 in rat brain: evaluation as a radioligand for central alpha 2-adrenoceptors. Int J Rad Appl Instrum B 19 (1992) 841-849
126. Hunyady L. Molecular mechanisms of angiotensin II receptor internalization. J Am Soc Nephrol 10 Suppl 11 (1999) S47-56
127. Jeanneteau, F. & Chao, M.V. (2006). Promoting neurotrophic effects by GPCR ligands. Novartis Found Symp 276, 181-189; discussion 189-192, 233-187, 275-181.
128. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 117 (2006) 18-24 quiz 25
129. Jones T. The enabling technologies needed for PET-based molecular imaging to support drug development. Drug Discov Today Technol 2 (2005) 305
130. Kapur S. A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Mol Psychiatry 3 (1998) 135-140
131. Kapur S., Barlow K., VanderSpek S.C., Javanmard M., and Nobrega J.N. Drug-induced receptor occupancy: substantial differences in measurements made in vivo vs ex vivo. Psychopharmacology (Berlin) 157 (2001) 168-171
132. Kapur S., Barsoum S.C., and Seeman P. Dopamine D(2) receptor blockade by haloperidol. (3)H-raclopride reveals much higher occupancy than EEDQ. Neuropsychopharmacology 23 (2000) 595-598
133. Kapur S., Remington G., Zipursky R.B., Wilson A.A., and Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 57 (1995) PL103-PL107
134. Kapur S., Zipursky R.B., and Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156 (1999) 286-293
135. Kapur S., Zipursky R.B., Remington G., Jones C., DaSilva J., Wilson A.A., et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155 (1998) 921-928
136. Kasper S., Tauscher J., Willeit M., Stamenkovic M., Neumeister A., Kufferle B., et al. Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder-implications for psychopharmacology. World J Biol Psychiatry 3 (2002) 133-146
137. Kegeles L.S., Slifstein M., Frankle W.G., Xu X., Hackett E., Bae S.A., et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology 33 (2008) 3111-3125
138. Keller M., Montgomery S., Ball W., Morrison M., Snavely D., Liu G., et al. Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 59 (2006) 216-223 Electronic publication 2005 Oct 24
139. Kenakin T.P. The classification of drugs and drug receptors in isolated tissues. Pharmacol Rev 36 (1984) 165-222
140. Kenakin T. Pharmacologic Analysis of Drug-Receptor Interaction (1993), Raven Press, New York 483
141. Kenakin T. Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci 18 (1997) 456-464
142. Kenakin T. Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25 (2004) 186-192
143. Kenakin T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol 65 (2004) 2-11
144. Kent J.M., Coplan J.D., Lombardo I., Hwang D.R., Huang Y., Mawlawi O., et al. Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652. Psychopharmacology (Berlin) 164 (2002) 341-348
145. Kessler R.M., Ansari M.S., Riccardi P., Li R., Jayathilake K., Dawant B., et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 31 (2006) 1991-2001
146. Kittler J.T., and Moss S.J. Neurotransmitter receptor trafficking and the regulation of synaptic strength. Traffic 2 (2001) 437-448
147. Kleven M.S., Barret-Grevoz C., Bruins Slot L., and Newman-Tancredi A. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 49 (2005) 135-143
148. Klimas M.T. Positron emission tomography and drug discovery: contributions to the understanding of pharmacokinetics, mechanism of action and disease state characterization. Mol Imaging Biol 4 (2002) 311-337
149. Kling M.A., Carson R.E., Borg L., Zametkin A., Matochik J.A., Schluger J., et al. Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther 295 (2000) 1070-1076
150. Knauer C.S., Campbell J.E., Galvan B., Bowman C., Osgood S., Buist S., et al. Validation of a rat in vivo [(3)H]M100907 binding assay to determine a translatable measure of 5-HT(2A) receptor occupancy. Eur J Pharmacol 591 (2008) 136-141
151. Knauer C.S., Campbell J., Galvan B., Hodge T., Reed J., Weber M., et al. Understanding intrinsic activity and receptor occupancy requirements necessary for benzodiazepine site ligand activity in the rat Vogel conflict model of anxiety. Soc Neurosci Abstr (2006)
152. Langlois X., te Riele P., Wintmolders C., Leysen J.E., and Jurzak M. Use of the beta-imager for rapid ex vivo autoradiography exemplified with central nervous system penetrating neurokinin 3 antagonists. J Pharmacol Exp Ther 299 (2001) 712-717
153. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20 (2000) 423-451
154. Lavreysen H., Pereira S.N., Leysen J.E., Langlois X., and Lesage A.S. Metabotropic glutamate 1 receptor distribution and occupancy in the rat brain: a quantitative autoradiographic study using [3H]R214127. Neuropharmacology 46 (2004) 609-619
155. Le S., Gruner J.A., Mathiasen J.R., Marino M.J., and Schaffhauser H. Correlation between ex vivo receptor occupancy and wake promoting activity of selective H3 receptor antagonists. J Pharmacol Exp Ther 325 (2008) 902-909
156. Lee C.M., and Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 27 (2006) 310-316
157. Li J., Fish R.L., Cook S.M., Tattersall F.D., and Atack J.R. Comparison of in vivo and ex vivo [3H]flumazenil binding assays to determine occupancy at the benzodiazepine binding site of rat brain GABAA receptors. Neuropharmacology 51 (2006) 168-172
158. Lingford-Hughes A. Human brain imaging and substance abuse. Curr Opin Pharmacol 5 (2005) 42-46
159. Lingford-Hughes A., Wilson S.J., Feeney A., Grasby P.G., and Nutt D.J. A proof-of-concept study using [11C]flumazenil PET to demonstrate that pagoclone is a partial agonist. Psychopharmacology (Berlin) 180 (2005) 789-791
160. Logan J., Wang G.J., Telang F., Fowler J.S., Alexoff D., Zabroski J., et al. Imaging the norepinephrine transporter in humans with (S,S)-[(11)C]O-methyl reboxetine and PET: problems and progress. Nucl Med Biol 34 (2007) 667-679 Electronic publication 2007 Jun 8
161. Lorenc-Koci E., Wardas J., Bartoszyk G.D., and Wolfarth S. Contribution of the serotonin 5-HT1A receptor agonism of 8-OH-DPAT and EMD 128130 to the regulation of haloperidol-induced muscle rigidity in rats. Neuropharmacology 45 (2003) 1057-1069
162. Mahan L.C., Motulsky H.J., and Insel P.A. Do agonists promote rapid internalization of beta-adrenergic receptors?. Proc Natl Acad Sci U S A 82 (1985) 6566-6570
163. Mamo D., Graff A., Mizrahi R., Shammi C.M., Romeyer F., and Kapur S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 164 (2007) 1411-1417
164. Martin B.R. Role of lipids and lipid signaling in the development of cannabinoid tolerance. Life Sci 77 (2005) 1543-1558
165. Martinot J.L., Paillere-Martinot M.L., Poirier M.F., Dao-Castellana M.H., Loc'h C., and Maziere B. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology (Berlin) 124 (1996) 154-158
166. Massoud T.F., and Gambhir S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17 (2003) 545-580
167. Matsui-Sakata A., Ohtani H., and Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 20 (2005) 368-378
168. McKernan R.M., Rosahl T.W., Reynolds D.S., Sur C., Wafford K.A., Atack J.R., et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 3 (2000) 587-592
169. McKinney M., Anderson D., and Vella-Rountree L. Different agonist-receptor active conformations for rat brain M1 and M2 muscarinic receptors that are separately coupled to two biochemical effector systems. Mol Pharmacol 35 (1989) 39-47
170. Melichar J.K., Hume S.P., Williams T.M., Daglish M.R., Taylor L.G., Ahmad R., et al. Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. J Pharmacol Exp Ther 312 (2005) 309-315
171. Melichar J.K., Nutt D.J., and Malizia A.L. Naloxone displacement at opioid receptor sites measured in vivo in the human brain. Eur J Pharmacol 459 (2003) 217-219
172. Meller E., and Bohmaker K. Differential receptor reserve for 5-HT1A receptor-mediated regulation of plasma neuroendocrine hormones. J Pharmacol Exp Ther 271 (1994) 1246-1252
173. Meller E., Bohmaker K., Namba Y., Friedhoff A.J., and Goldstein M. Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol Pharmacol 31 (1987) 592-598
174. Meller E., Chalfin M., and Bohmaker K. Serotonin 5-HT1A receptor-mediated hypothermia in mice: absence of spare receptors and rapid induction of tolerance. Pharmacol Biochem Behav 43 (1992) 405-411
175. Meller E., Enz A., and Goldstein M. Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity. Eur J Pharmacol 155 (1988) 151-154
176. Meller E., Goldstein M., and Bohmaker K. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists. Mol Pharmacol 37 (1990) 231-237
177. Meller E., Hizami R., and Kreuter L. Hypothermia in mice: D2 dopamine receptor mediation and absence of spare receptors. Pharmacol Biochem Behav 32 (1989) 141-145
178. Meller E., Puza T., Miller J.C., Friedhoff A.J., and Schweitzer J.W. Receptor reserve for D2 dopaminergic inhibition of prolactin release in vivo and in vitro. J Pharmacol Exp Ther 257 (1991) 668-675
179. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 1159-1172
180. Meyer J.H., Wilson A.A., Ginovart N., Goulding V., Hussey D., Hood K., et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 158 (2001) 1843-1849
181. Meyer J.H., Wilson A.A., Sagrati S., Hussey D., Carella A., Potter W.Z., et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161 (2004) 826-835
182. Milligan G. Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol Pharmacol 64 (2003) 1271-1276
183. Milligan G. G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol 66 (2004) 1-7
184. Milligan G., Canals M., Pediani J.D., Ellis J., and Lopez-Gimenez J.F. The role of GPCR dimerisation/oligomerisation in receptor signalling. Ernst Schering Found Symp Proc 2 (2006) 145-161
185. Moller H.J. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 1101-1111
186. Montanez S., Daws L.C., Gould G.G., and Frazer A. Serotonin (5-HT) transporter (SERT) function after graded destruction of serotonergic neurons. J Neurochem 87 (2003) 861-867
187. Morfis M., Christopoulos A., and Sexton P.M. RAMPs: 5 years on, where to now?. Trends Pharmacol Sci 24 (2003) 596-601
188. Morgan D., and Picker M.J. The mu opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the mu opioid receptor. Psychopharmacology (Berlin) 140 (1998) 20-28
189. Murray F., Kennedy J., Hutson P.H., Elliot J., Huscroft I., Mohnen K., et al. Modulation of [3H]MK-801 binding to NMDA receptors in vivo and in vitro. Eur J Pharmacol 397 (2000) 263-270
190. Narendran R., Hwang D.R., Slifstein M., Talbot P.S., Erritzoe D., Huang Y., et al. In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride. Synapse 52 (2004) 188-208
191. Natesan S., Reckless G.E., Nobrega J.N., Fletcher P.J., and Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31 (2006) 1854-1863
192. Nayebi A.R., and Charkhpour M. Role of 5-HT(1A) and 5-HT(2) receptors of dorsal and median raphe nucleus in tolerance to morphine analgesia in rats. Pharmacol Biochem Behav 83 (2006) 203-207
193. Need A.B., Davis R.J., Alexander-Chacko J.T., Eastwood B., Chernet E., Phebus L.A., et al. The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats. Psychopharmacology (Berlin) 184 (2006) 26-35
194. Need A.B., McKinzie J.H., Mitch C.H., Statnick M.A., and Phebus L.A. In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously. Life Sci 81 (2007) 1389-1396 Electronic publication 2007 Sep 19
195. Nelson C.P., and Challiss R.A. "Phenotypic" pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology. Biochem Pharmacol 73 (2007) 737-751
196. Newman-Tancredi A., Assie M.B., Leduc N., Ormiere A.M., Danty N., and Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 8 (2005) 341-356
197. Newman-Tancredi A., Rivet J.M., Cussac D., Touzard M., Chaput C., Marini L., et al. Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn Schmiedebergs Arch Pharmacol 368 (2003) 188-199
198. Nordstrom A.L., Farde L., and Halldin C. High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology (Berl) 110 (1993) 365-367
199. Nordstrom A.L., Farde L., Wiesel F.A., Forslund K., Pauli S., Halldin C., et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33 (1993) 227-235
200. Nordstrom A.L., Farde L., Nyberg S., Karlsson P., Halldin C., and Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152 (1995) 1444-1449
201. Nordstrom A.L., Nyberg S., Olsson H., and Farde L. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. Arch Gen Psychiatry 55 (1998) 283-284
202. Nyberg S., Eriksson B., Oxenstierna G., Halldin C., and Farde L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 156 (1999) 869-875
203. Nyberg S., Farde L., Bartfai A., and Halldin C. Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol 10 (1995) 221-227
204. Nyberg S., Farde L., and Halldin C. Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients. Psychiatry Res 67 (1996) 163-171
205. Nyberg S., Nakashima Y., Nordstrom A.L., Halldin C., and Farde L. Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response. Br J Psychiatry Suppl (1996) 40-44
206. Nyberg S., Farde L., and Halldin C. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 16 (1997) 1-7
207. Nyberg S., Nilsson U., Okubo Y., Halldin C., and Farde L. Implications of brain imaging for the management of schizophrenia. Int Clin Psychopharmacol 13 Suppl 3 (1998) S15-20
208. Nyberg S., Olsson H., Nilsson U., Maehlum E., Halldin C., and Farde L. Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology (Berl) 162 (2002) 37-41
209. Ohlsen R.I., and Pilowsky L.S. The place of partial agonism in psychiatry: recent developments. J Psychopharmacol 19 (2005) 408-413
210. Olsen C.K., Brennum L.T., and Kreilgaard M. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Eur J Pharmacol 584 (2008) 318-327
211. Olsson H., and Farde L. Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy-a simulation study based on experimental data. Neuroimage 14 (2001) 936-945
212. Onaran H.O., and Costa T. Agonist efficacy and allosteric models of receptor action. Ann N Y Acad Sci 812 (1997) 98-115
213. Orlefors H., Sundin A., Fasth K.J., Oberg K., Langstrom B., Eriksson B., et al. Demonstration of high monoaminoxidase-A levels in neuroendocrine gastroenteropancreatic tumors in vitro and in vivo-tumor visualization using positron emission tomography with 11C-harmine. Nucl Med Biol 30 (2003) 669-679
214. Otano A., Garcia-Osta A., Ballaz S., Frechilla D., and Del Rio J. Facilitation by 8-OH-DPAT of passive avoidance performance in rats after inactivation of 5-HT(1A) receptors. Br J Pharmacol 128 (1999) 1691-1698
215. Owens M.J., Knight D.L., and Nemeroff C.B. Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatry 47 (2000) 842-845
216. Parameswaran N., and Spielman W.S. RAMPs: the past, present and future. Trends Biochem Sci 31 (2006) 631-638
217. Pareto D., Alvarado M., Hanrahan S.M., and Biegon A. In vivo occupancy of female rat brain estrogen receptors by 17beta-estradiol and tamoxifen. Neuroimage 23 (2004) 1161-1167
218. Paronis C.A., and Holtzman S.G. Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats. J Pharmacol Exp Ther 262 (1992) 1-9
219. Passchier J., Gee A., Willemsen A., Vaalburg W., and van Waarde A. Measuring drug-related receptor occupancy with positron emission tomography. Methods 27 (2002) 278-286
220. Patel S., Fernandez-Garcia E., and Hutson P.H. An in vivo binding assay to determine central alpha(1)-adrenoceptor occupancy using [(3)H]prazosin. Brain Res Brain Res Protoc 8 (2001) 191-198
221. Perry D.C., Rosenbaum J.S., Kurowski M., and Sadee W. [3H]Etorphine receptor binding in vivo. Small fractional occupancy elicits analgesia. Mol Pharmacol 21 (1982) 272-279
222. Pilowsky L.S. Probing targets for antipsychotic drug action with PET and SPET receptor imaging. Nucl Med Commun 22 (2001) 829-833
223. Pinto W., and Battaglia G. In vivo EEDQ dose-dependently inactivates rat brain 5-HT receptors but not 5-HT uptake sites. Neuroreport 5 (1993) 61-64
224. Pliska V. Partial agonism: mechanisms based on ligand-receptor interactions and on stimulus-response coupling. J Recept Signal Transduct Res 19 (1999) 597-629
225. Prinster S.C., Hague C., and Hall R.A. Heterodimerization of g protein-coupled receptors: specificity and functional significance. Pharmacol Rev 57 (2005) 289-298
226. Qing F., Rahman S.U., Rhodes C.G., Hayes M.J., Sriskandan S., Ind P.W., et al. Pulmonary and cardiac beta-adrenoceptor density in vivo in asthmatic subjects. Am J Respir Crit Care Med 155 (1997) 1130-1134
227. Quick M.W., and Lester R.A. Desensitization of neuronal nicotinic receptors. J Neurobiol 53 (2002) 457-478
228. Rabiner E.A., Gunn R.N., Wilkins M.R., Sedman E., and Grasby P.M. Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride. J Psychopharmacol 16 (2002) 195-199
229. Riemann B., Schafers K.P., Schober O., and Schafers M. Small animal PET in preclinical studies: opportunities and challenges. Q J Nucl Med Mol Imaging 52 (2008) 215-221
230. Rosenbaum J.S., Holford N.H., and Sadee W. Opiate receptor binding-effect relationship: sufentanil and etorphine produce analgesia at the mu-site with low fractional receptor occupancy. Brain Res 291 (1984) 317-324
231. Ruffolo Jr. R.R. Important concepts of receptor theory. J Auton Pharmacol 2 (1982) 277-295
232. Ruffolo Jr. R.R. Spare alpha adrenoceptors in the peripheral circulation: excitation-contraction coupling. Fed Proc 45 (1986) 2341-2346
233. Ruffolo Jr. R.R., and Nichols A.J. The relationship of receptor reserve and agonist efficacy to the sensitivity of alpha-adrenoceptor-mediated vasopressor responses to inhibition by calcium channel antagonists. Ann N Y Acad Sci 522 (1988) 361-376
234. Sadzot B., Mayberg H.S., and Frost J.J. Detection and quantification of opiate receptors in man by positron emission tomography. Potential applications to the study of pain. Neurophysiol Clin 20 (1990) 323-334
235. Sakaue M., Ago Y., Sowa C., Koyama Y., Baba A., and Matsuda T. The 5-HT1A receptor agonist MKC-242 increases the exploratory activity of mice in the elevated plus-maze. Eur J Pharmacol 458 (2003) 141-144
236. Samama P., Cotecchia S., Costa T., and Lefkowitz R.J. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268 (1993) 4625-4636
237. Sarter M., McGaughty J., Holley L.A., and D. P. Behavioural facilitation and cognition enhancement. In: Sarter M., N. D.J., and L. R.G. (Eds). Benzodiazepine Receptor Inverse Agonists (1995), Wiley-Liss 213-242
238. Scatton B., Claustre Y., Cudennec A., Oblin A., Perrault G., Sanger D.J., et al. Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol 12 Suppl 2 (1997) S29-S36
239. Schoemaker H., Claustre Y., Fage D., Rouquier L., Chergui K., Curet O., et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280 (1997) 83-97
240. Schotte A., Janssen P.F., Bonaventure P., and Leysen J.E. Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study. Histochem J 28 (1996) 791-799
241. Scott-Stevens P., Atack J.R., Sohal B., and Worboys P. Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417. Biopharm Drug Dispos 26 (2005) 13-20
242. Seabrook G.R., Easter A., Dawson G.R., and Bowery B.J. Modulation of long-term potentiation in CA1 region of mouse hippocampal brain slices by GABAA receptor benzodiazepine site ligands. Neuropharmacology 36 (1997) 823-830
243. Seifert R., Wenzel-Seifert K., Gether U., and Kobilka B.K. Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. J Pharmacol Exp Ther 297 (2001) 1218-1226
244. Seneca N., Finnema S.J., Farde L., Gulyas B., Wikstrom H.V., Halldin C., et al. Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride. Synapse 59 (2006) 260-269
245. Seneca N., Gulyas B., Varrone A., Schou M., Airaksinen A., Tauscher J., et al. Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[(18)F]FMeNER-D (2). Psychopharmacology (Berlin) 188 (2006) 119-127
246. Sethy V.H., and Francis J.W. Pharmacokinetics of buspirone as determined by ex vivo (3H)-DPAT binding. Life Sci 42 (1988) 1045-1048
247. Sexton P.M., Morfis M., Tilakaratne N., Hay D.L., Udawela M., Christopoulos G., et al. Complexing receptor pharmacology: modulation of family B G protein-coupled receptor function by RAMPs. Ann N Y Acad Sci 1070 (2006) 90-104
248. Shieh C.C., Feng J., Buckner S.A., Brioni J.D., Coghlan M.J., Sullivan J.P., et al. Functional implication of spare ATP-sensitive K(+) channels in bladder smooth muscle cells. J Pharmacol Exp Ther 296 (2001) 669-675
249. Shinotoh H., Fukushi K., Nagatsuka S., and Irie T. Acetylcholinesterase imaging: its use in therapy evaluation and drug design. Curr Pharm Des 10 (2004) 1505-1517
250. Slifstein M., Kegeles L.S., Gonzales R., Frankle W.G., Xu X., Laruelle M., et al. [11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT(2A) receptors: a PET study in healthy human subjects. J Cereb Blood Flow Metab 27 (2007) 1733-1741
251. Stathis M., Scheffel U., Lever S.Z., Boja J.W., Carroll F.I., and Kuhar M.J. Rate of binding of various inhibitors at the dopamine transporter in vivo. Psychopharmacology (Berl) 119 (1995) 376-384
252. Stean T.O., Hirst W.D., Thomas D.R., Price G.W., Rogers D., Riley G., et al. Pharmacological profile of SB-357134: a potent, selective, brain penetrant, and orally active 5-HT(6) receptor antagonist. Pharmacol Biochem Behav 71 (2002) 645-654
253. Stephenson C.M., Bigliani V., Jones H.M., Mulligan R.S., Acton P.D., Visvikis D., et al. Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study. Br J Psychiatry 177 (2000) 408-415
254. Sternfeld F., Carling R.W., Jelley R.A., Ladduwahetty T., Merchant K.J., Moore K.W., et al. Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers. J Med Chem 47 (2004) 2176-2179
255. Stone J.M., Bressan R.A., Erlandsson K., Ell P.J., and Pilowsky L.S. Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride. Psychopharmacology (Berl) 180 (2005) 664-669
256. Strosberg A.D. Anti-receptor antibodies as ligands. In: Hulme E.C. (Ed). Receptor-Ligand Interactions, a Practical Approach (1992), IRL Press, New York
257. Su D.S., Markowitz M.K., Murphy K.L., Wan B.L., Zrada M.M., Harrell C.M., et al. Development of an efficient and selective radioligand for bradykinin B1 receptor occupancy studies. Bioorg Med Chem Lett 14 (2004) 6045-6048
258. Suhara T., Takano A., Sudo Y., Ichimiya T., Inoue M., Yasuno F., et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 60 (2003) 386-391
259. Sybirska E., Seibyl J.P., Bremner J.D., Baldwin R.M., al-Tikriti M.S., Bradberry C., et al. [123I]iomazenil SPECT imaging demonstrates significant benzodiazepine receptor reserve in human and nonhuman primate brain. Neuropharmacology 32 (1993) 671-680
260. Szekeres P.G., Koenig J.A., and Edwardson J.M. The relationship between agonist intrinsic activity and the rate of endocytosis of muscarinic receptors in a human neuroblastoma cell line. Mol Pharmacol 53 (1998) 759-765
261. Talbot P.S., and Laruelle M. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 12 (2002) 503-511
262. Tallarida R.J. Pharmacologic methods for identification of receptors. Life Sci 43 (1988) 2169-2176
263. Tamagnan G.D., Brenner E., Alagille D., Staley J.K., Haile C., Koren A., et al. Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg Med Chem Lett 17 (2007) 533-537 Electronic publication 2006 Oct 12
264. Taylor S.J., Michel A.D., and Kilpatrick G.J. In vivo occupancy of histamine H3 receptors by thioperamide and (R)-alpha-methylhistamine measured using histamine turnover and an ex vivo labeling technique. Biochem Pharmacol 44 (1992) 1261-1267
265. Terasaki W.L., and Brooker G. [125I]Iodohydroxybenzylpindolol binding sites on intact rat glioma cells. Evidence for beta-adrenergic receptors of high coupling efficiency. J Biol Chem 253 (1978) 5418-5425
266. Terrillon S., and Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep 5 (2004) 30-34
267. Tsukada H., Fukumoto D., Nishiyama S., Sato K., and Kakiuchi T. Transient focal ischemia affects the cAMP second messenger system and coupled dopamine D1 and 5-HT1A receptors in the living monkey brain: a positron emission tomography study using microdialysis. J Cereb Blood Flow Metab 24 (2004) 898-906
268. Urban J.D., Clarke W.P., von Zastrow M., Nichols D.E., Kobilka B., Weinstein H., et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320 (2007) 1-13
269. Vanhoutte P.M., and Miller V.M. Alpha 2-adrenoceptors and endothelium-derived relaxing factor. Am J Med 87 (1989) 1S-5S
270. van Rossum J., and Ariens E.J. Receptor-reserve and threshold-phenomena. II. Theories on drug-action and a quantitative approach to spare receptors and threshold values. Arch Int Pharmacodyn Ther 136 (1962) 385-413
271. Van Vliet B.J., Ronken E., Tulp M., Feenstra R., Kruse C.G., and Long S.K. DU 127090: a highly potent, atypical dopamine receptor ligand - high potency but low efficacy at dopamine D2 receptors in vitro. Eur Neuropsychopharmacol 10 (2000) S294
272. van Waarde A. Measuring receptor occupancy with PET. Curr Pharm Des 6 (2000) 1593-1610
273. van Waarde A., Maas B., Doze P., Slart R.H., Frijlink H.W., Vaalburg W., et al. Positron emission tomography studies of human airways using an inhaled beta-adrenoceptor antagonist, S-11C-CGP 12388. Chest 128 (2005) 3020-3027
274. Venault P., Chapouthier G., de Carvalho L.P., Simiand J., Morre M., Dodd R.H., et al. Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature 321 (1986) 864-866
275. Visser S.A., Wolters F.L., Gubbens-Stibbe J.M., Tukker E., Van Der Graaf P.H., Peletier L.A., et al. Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations. J Pharmacol Exp Ther 304 (2003) 88-101
276. Visser T.J., van Waarde A., van der Mark T.W., Kraan J., Elsinga P.H., Pruim J., et al. Characterization of pulmonary and myocardial beta-adrenoceptors with S-1′-[fluorine-18]fluorocarazolol. J Nucl Med 38 (1997) 169-174
277. Volkow N.D., Fowler J.S., Wang G.J., and Goldstein R.Z. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Neurobiol Learn Mem 78 (2002) 610-624
278. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Franceschi D., Maynard L., et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 43 (2002) 181-187
279. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Logan J., Ding Y.S., et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155 (1998) 1325-1331
280. Wadenberg M.L., Soliman A., VanderSpek S.C., and Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25 (2001) 633-641
281. Waelbroeck I. Kinetics versus equilibrium: the importance of GTP in GPCR activation. Trends Pharmacol Sci 20 (1999) 477-481
282. Wafford K.A. GABAA receptor subtypes: any clues to the mechanism of benzodiazepine dependence?. Curr Opin Pharmacol 5 (2005) 47-52
283. Waldhoer M., Fong J., Jones R.M., Lunzer M.M., Sharma S.K., Kostenis E., et al. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci U S A 102 (2005) 9050-9055
284. Wang J., and Maurer L. Positron emission tomography: applications in drug discovery and drug development. Curr Top Med Chem 5 (2005) 1053-1075
285. Wang Z.J., and Wang L.X. Phosphorylation: a molecular switch in opioid tolerance. Life Sci 79 (2006) 1681-1691
286. Waterhouse R.N., and Zhao J. In vivo tomographic imaging studies of neurodegeneration and neuroprotection: a review. Methods Mol Biol 399 (2007) 215-233
287. Watts V.J. Molecular mechanisms for heterologous sensitization of adenylate cyclase. J Pharmacol Exp Ther 302 (2002) 1-7
288. Weiss J.M., Morgan P.H., Lutz M.W., and Kenakin T.P. The cubic ternary complex receptor-occupancy model. I. Model description. J Theor Biol 178 (1996) 151-167
289. Wenger B.W., Bryant D.L., Boyd R.T., and McKay D.B. Evidence for spare nicotinic acetylcholine receptors and a beta 4 subunit in bovine adrenal chromaffin cells: studies using bromoacetylcholine, epibatidine, cytisine and mAb35. J Pharmacol Exp Ther 281 (1997) 905-913
290. Wesolowska A., Paluchowska M., and Chojnacka-Wojcik E. Involvement of presynaptic 5-HT(1A) and benzodiazepine receptors in the anticonflict activity of 5-HT(1A) receptor antagonists. Eur J Pharmacol 471 (2003) 27-34
291. Wesolowska A., Paluchowska M.H., Golembiowska K., and Chojnacka-Wojcik E. Pharmacological characterization of MP349, a novel 5-HT1A-receptor antagonist with anxiolytic-like activity, in mice and rats. J Pharm Pharmacol 55 (2003) 533-543
292. Whaley B.S., Yuan N., Birnbaumer L., Clark R.B., and Barber R. Differential expression of the beta-adrenergic receptor modifies agonist stimulation of adenylyl cyclase: a quantitative evaluation. Mol Pharmacol 45 (1994) 481-489
293. Yamada Y., Sugiura M., Higo K., Ozeki T., Takayanagi R., Okuyama K., et al. Receptor occupancy theory-based analysis of antiemetic effects and standard doses of 5-HT3 receptor antagonists in cancer patients. Cancer Chemother Pharmacol 54 (2004) 185-190
294. Yang C.R., and Svensson K.A. Allosteric modulation of NMDA receptor via elevation of brain glycine and d-serine: the therapeutic potentials for schizophrenia. Pharmacol Ther 120 (2008) 317-332
295. Yasui M., Kawasaki K., Matsushita A., and Satoh M. Benzodiazepine inverse agonists augment long-term potentiation in CA1 and CA3 of guinea pig hippocampal slices. Neuropharmacology 32 (1993) 127-131
296. Yokoi F., Grunder G., Biziere K., Stephane M., Dogan A.S., Dannals R.F., et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27 (2002) 248-259
297. Yokoo H., Goldstein M., and Meller E. Receptor reserve at striatal dopamine receptors modulating the release of [3H]dopamine. Eur J Pharmacol 155 (1988) 323-327
298. Zhang X., Bao L., and Guan J.S. Role of delivery and trafficking of delta-opioid peptide receptors in opioid analgesia and tolerance. Trends Pharmacol Sci 27 (2006) 324-329
299. Zhu B.T. The competitive and noncompetitive antagonism of receptor-mediated drug actions in the presence of spare receptors. J Pharmacol Toxicol Methods 29 (1993) 85-91
300. Zimmer L., Rbah L., Giacomelli F., Le Bars D., and Renaud B. A reduced extracellular serotonin level increases the 5-HT1A PET ligand 18F-MPPF binding in the rat hippocampus. J Nucl Med 44 (2003) 1495-1501
301. Zubieta J., Greenwald M.K., Lombardi U., Woods J.H., Kilbourn M.R., Jewett D.M., et al. Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology 23 (2000) 326-334
302. Zuideveld K.P., Van der Graaf P.H., Newgreen D., Thurlow R., Petty N., Jordan P., et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of 5-HT1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats. J Pharmacol Exp Ther 308 (2004) 1012-1020
303. Zuo Z. The role of opioid receptor internalization and beta-arrestins in the development of opioid tolerance. Anesth Analg 101 (2005) 728-734